Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): Implications for GLP-1 measurements in clinical studies

Diabetes, Obesity and Metabolism

Volumn 16, Issue 11, 2014, Pages 1155-1164

  Bak, M J ^a,b   Wewer Albrechtsen, N J ^a   Pedersen, J ^a   Knop, F K ^b   Vilsboll T ^b   Jorgensen N B ^b   Hartmann, B ^a   Deacon, C F ^a   Dragsted, L O ^b   Holst, J J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cross reactivity; Enzyme linked immunosorbent assay; Glucagon like peptide 1; Precision; Radioimmunoassay; Sensitivity; Specificity

Indexed keywords

BUFFER; GLUCAGON LIKE PEPTIDE 1; VALINE PYRROLIDIDE; GLUCAGON; PEPTIDE FRAGMENT;

ARTICLE; BIOASSAY; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; CROSS REACTION; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; NORMAL HUMAN; PROTEIN BLOOD LEVEL; QUALITY CONTROL; RADIOIMMUNOASSAY; SENSITIVITY AND SPECIFICITY; AMINO ACID SEQUENCE; BLOOD; CHEMISTRY; EVALUATION STUDY; IMMUNOLOGY;

AMINO ACID SEQUENCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; PEPTIDE FRAGMENTS; RADIOIMMUNOASSAY; SENSITIVITY AND SPECIFICITY;

EID: 84914154785     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12352     Document Type: Article

References (23)

1. Holst JJ. Incretin hormones and the satiation signal. Int J Obes (Lond) 2013; 37: 1161-1168.
2. Wewer Albrechtsen NJ, Kuhre RE, Deacon CF, Holst JJ. Targeting the intestinal L-cell for obesity and type 2 diabetes treatment. Exp Rev Endocrinol Metab 2014; 9: 61-72.
3. Deacon CF, Ahren B. Physiology of incretins in health and disease. Rev Diabet Stud 2011; 8: 293-306.
4. Kuhre RE, Albrechtsen NW, Windelov JA, Svendsen B, Hartmann B, Holst JJ. GLP-1 amidation efficiency along the length of the intestine in mice, rats and pigs and in GLP-1 secreting cell lines. Peptides 2014; 55: 52-57.
5. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994; 43: 535-539.
6. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80: 952-957.
7. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 1996; 271: E458-E464.
8. Hjøllund KR, Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs. Diabetologia 2011; 54: 2206-2208.
9. Ahrén B, Simonsson E, Larsson H et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002; 25: 869-875.
10. Dai H, Gustavson SM, Preston GM, Eskra JD, Calle R, Hirshberg B. Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects. Diabetes Obes Metab 2008; 10: 506-513.
11. Bak MJ, Albrechtsen NW, Pedersen J et al. Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. Eur J Endocrinol 2014; 170: 529-538.
12. Knop FKHK, Pedersen J, Hendel JW, Poulsen SS, Holst JJ, Vilsbøll T. Prohormone convertase 2 positive enteroendocrine cells are more abundant in patients with type 2 diabetes-a potential source of gut-derived glucagon. Diabetes 2011; 60: 1764.
13. Jørgensen NB, Jacobsen SH, Dirksen C et al. Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with type 2 diabetes and normal glucose tolerance. Am J Physiol Endocrinol Metab 2012; 303: E122-E131.
14. Deacon CF, Holst JJ. Immunoassays for the incretin hormones GIP and GLP-1. Best Pract Res Clin Endocrinol Metab 2009; 23: 425-432.
15. Runchey SS, Valsta LM, Schwarz Y et al. Effect of low- and high-glycemic load on circulating incretins in a randomized clinical trial. Metabolism 2013; 62: 188-195.
16. Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 2013; 98: 3446-3453.
17. Sukkar SG, Vaccaro A, Ravera GB et al. Appetite control and gastrointestinal hormonal behavior (CCK, GLP-1, PYY 1-36) following low doses of a whey protein-rich nutraceutic. Med J Nutrition Metab 2013; 6: 259-266.
18. Wu T, Bound MJ, Standfield SD, Jones KL, Horowitz M, Rayner CK. Effects of taurocholic acid on glycemic, glucagon-like peptide-1, and insulin responses to small intestinal glucose infusion in healthy humans. J Clin Endocrinol Metab 2013; 98: E718-E722.
19. Bodinham CL, Al-Mana NM, Smith L, Robertson MD. Endogenous plasma glucagon-like peptide-1 following acute dietary fibre consumption. Br J Nutr 2013; 110: 1429-1433.
20. Jiménez A, Casamitjana R, Viaplana-Masclans J, Lacy A, Vidal J. GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes after gastric bypass surgery. Diabetes Care 2013; 36: 2062-2069.
21. Chronaiou A, Tsoli M, Kehagias I, Leotsinidis M, Kalfarentzos F, Alexandrides T. Lower ghrelin levels and exaggerated postprandial peptide-YY, glucagon-like peptide-1, and insulin responses, after gastric fundus resection, in patients undergoing Roux-en-Y gastric bypass: a randomized clinical trial. Obes Surg 2012; 22: 1761-1770.
22. Geloneze B, Geloneze SR, Chaim E et al. Metabolic surgery for non-obese type 2 diabetes: incretins, adipocytokines, and insulin secretion/resistance changes in a 1-year interventional clinical controlled study. Ann Surg 2012; 256: 72-78.
23. Lee W-J, Chen C-Y, Chong K, Lee Y-C, Chen S-C, Lee S-D. Changes in postprandial gut hormones after metabolic surgery: a comparison of gastric bypass and sleeve gastrectomy. Surg Obes Relat Dis 2011; 7: 683-690.